Taken together, these findings suggest that development of pharmacotherapies targeting mGlu5 to ameliorate cognitive impairment, which interferes with behavioral treatment for MUD, may be of particular interest (Petzold et al, 2021). Here, GRM5 is linked to Cognitive impairment.